Early results from a new, pioneering chimeric antigen receptor (CAR) T cell immunotherapy trial found using a bilateral attack achieves a more robust defense and helps avoid relapse.
from Latest Science News -- ScienceDaily https://www.sciencedaily.com/releases/2021/04/210411114051.htm
from Latest Science News -- ScienceDaily https://www.sciencedaily.com/releases/2021/04/210411114051.htm
New CAR T approach minimizes resistance, helps avoid relapse in non-Hodgkin's B-cell lymphoma
![New CAR T approach minimizes resistance, helps avoid relapse in non-Hodgkin's B-cell lymphoma]()
Reviewed by cmakigo
on
April 12, 2021
Rating:
No comments:
Post a Comment